Janoshik Analytical: Independent Peptide Testing | Peptide Intel Hub

Janoshik Analytical is an EU-based independent analytical laboratory specialising in research-peptide and small-molecule analysis. The laboratory is operationally independent from peptide manufacturers and suppliers, which is the essential property that gives its reports weight: a Janoshik COA carries no commercial incentive to over-report purity or under-report related impurities.

Janoshik routinely publishes its analytical methods, instrumentation and acceptance criteria, and its reports use a consistent layout that is easily cross-referenced against the batch number on the vial cap. Across the research-peptide industry, a Janoshik report is treated as the minimum credible evidence that a batch has been independently verified.

A standard Janoshik peptide report contains: the batch identifier, the requested compound, the HPLC chromatogram with peak integration, the main-peak purity percentage, the related-impurities profile, the mass-spectrometry chromatogram with theoretical and measured molecular weight, the water (Karl Fischer) content, and the analyst's signature with the report date.

The HPLC chromatogram is the single most important panel: it shows the main peak (the target peptide), the area under that peak as a percentage of total integrated peak area, and the secondary peaks (the related impurities). The mass-spectrometry panel confirms identity — that the main peak is in fact the compound named on the label and not a same-mass-region impurity or a truncated sequence.

Best practice is for a batch to be sent to Janoshik (or, where batch chemistry calls for an orthogonal method, to a second independent laboratory) before any vial is released. The COA should match the batch number printed on the vial cap and travel with the material, so the receiving laboratory can re-verify the chain of custody on arrival.

A typical minimum specification for batch release is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound. Batches that do not meet the specification are not released, regardless of supply pressure.

A receiving researcher should perform three checks before reconstitution: (1) the batch number on the vial cap matches the batch number on the Janoshik report; (2) the report date is within the shelf-life window for the compound; (3) the report identifies the correct compound at the correct molecular weight.

If any of those three fail, do not reconstitute the vial — raise it with the supplier before use and ask them to investigate the discrepancy. The cross-reference takes under a minute and is the single best protection against handling a mis-labelled or mis-shipped vial.

Janoshik is not the only credible independent peptide laboratory — Anresco, Auriga Research, and several university-hosted core facilities also produce credible COAs. The advantage of Janoshik is consistency: the report format is the same across suppliers and across years, which makes cross-supplier batch comparison straightforward.

A verified supplier occasionally uses an orthogonal laboratory when batch chemistry calls for a second-instrument confirmation, when the receiving institution has a specific accredited-laboratory requirement, or when Janoshik's queue would delay release beyond the project window. The default remains Janoshik for the cross-supplier comparability it offers.

A Janoshik COA is an analytical report, not a sterility certificate, not a clinical authorisation and not a Material Safety Data Sheet. The report covers chemical identity, purity and related impurities for the analysed sample; it does not certify that the rest of the batch is sterile, does not authorise human use, and does not replace institutional ethics or biosafety procedures.

A verified supplier issues sterility, MSDS, CoO and CoC documentation separately on request — most commonly for institutional buyers operating under formal procurement systems. The Janoshik COA sits alongside that documentation, not as a substitute for it.

A reputable supplier publishes every batch COA, indexed by compound and batch number. New batches appear within 24 hours of independent release. The same COA is also bundled with the shipment, printed and electronic, so the receiving researcher can confirm the report before reconstitution.

If a batch number printed on a vial cannot be found in the supplier's COA archive, flag it to the supplier immediately — that is a chain-of-custody flag and a reputable supplier will replace the batch while the discrepancy is investigated.

Research-peptide supply has matured fast over the past three years and so has the pressure on suppliers to short-cut analytical verification. Supplier-funded in-house COAs are the most common short-cut: they look like a Janoshik report at a glance but the analytical laboratory is not commercially independent from the supplier, which removes the property that gives a third-party COA its weight.

A verified supplier's position is straightforward: a batch without an independent COA does not ship. Janoshik is the default, an orthogonal independent laboratory is the fallback, and the COA travels with every shipment to every research jurisdiction the supplier serves.

The landscape of peptide therapeutics, particularly with the rise of biosimilars and new pharmacological treatments, underscores a critical need for rigorous quality and verification processes. Tumor necrosis factor (TNF-alpha) inhibitors, such as adalimumab, have successfully treated autoimmune inflammatory diseases (PMID 30554330). Biosimilars like SB5, an adalimumab biosimilar, aim to reduce the financial burden of such treatments while potentially offering improved stability and prolonged use (PMID 30554330). However, the market for various peptide products, including those sold online, presents significant quality and safety challenges, necessitating robust verification methods.

The proliferation of unregulated online sales, especially for drugs like semaglutide used off-label for cosmetic weight loss, has led to concerns about substandard and falsified products (PMID 39509151). A multifactor investigation into online sales of semaglutide identified 134 links (42.3%) directing users to 59 unique illegal online pharmacy websites from a total of 317 online pharmacy links (PMID 39509151). Test purchases from these illegal online pharmacies resulted in products considered probable substandard and falsified, with visual inspection indicating noncompliance in 59%-63% of evaluated criteria (PMID 39509151). This highlights the substantial risks associated with unregulated sources and the imperative for comprehensive quality control in peptide manufacturing and distribution.

Maintaining the physicochemical and biological stability of biosimilars is paramount for patient safety and treatment efficacy. SB5, an adalimumab biosimilar, has demonstrated equivalent efficacy and comparable safety to its reference product in clinical trials (PMID 30554330). This biosimilar is approved for storage for 36 months at 2-8 °C and can be stored at room temperature (25 °C) for a maximum of 14 days (PMID 30554330). A study evaluating the stability of 36-months-aged SB5 at room temperature (25 ± 2 °C) and 60 ± 5% relative humidity for 4 weeks, an extended period beyond the European Union's approved 14 days, showed promising results (PMID 30554330).

Three independent batches of 36-months-aged SB5 were tested at 0, 2, and 4 weeks. The study found consistency in color, clarity, visible particles, pH, protein concentration, and particulate matter across batches, with all test results meeting acceptance criteria at each time point (PMID 30554330). Percent charge variance was maintained over time, and the percent of high molecular weight species detected, total purity, relative binding activity by TNF-alpha, and relative potency by TNF-alpha neutralization did not change within each batch, remaining within acceptance criteria (PMID 30554330). These findings indicate that 36-months-aged SB5 is physicochemically and biologically stable for 4 weeks at 25 ± 2 °C and 60 ± 5% RH, which is two weeks longer than the alternative storage condition approved by the European Medicines Agency (PMID 30554330).

While pharmaceutical quality control often relies on LC-based procedures, these methods can sometimes be 'blind' to specific impurities, highlighting the need for more versatile detection techniques. Nuclear Magnetic Resonance (NMR) spectroscopy offers a powerful and often more judicious approach for detecting undeclared constituents in active pharmaceutical ingredients (APIs) and even research chemicals (PMID 31671336). Research chemicals are frequently trusted without suspicion of flaws or adulteration, but experimental verification is crucial (PMID 31671336).

A report demonstrated how NMR analysis uncovered substantial amounts of mannitol (20% and 43% w/w) as an undeclared constituent in two commercially sourced custom synthetic peptides, DR and DRVYI (PMID 31671336). Quantitative 1H NMR (qHNMR) successfully detected and quantified this highly polar and UV-transparent adulterant, even using a 60 MHz benchtop instrument (PMID 31671336). Quantum-mechanical 1H iterative Full Spin Analysis (HiFSA) not only unambiguously identified both mannitol and the peptides but also confirmed the quantitative results (PMID 31671336). These cases underscore that experimental verification should supersede trust in both pharmaceutical and research quality control, emphasizing the utility of both established high-field and re-evolving low-field benchtop qHNMR (PMID 31671336).

The global surge in obesity has driven the development of pharmacological treatments like glucagon-like peptide 1 agonists such as semaglutide (PMID 39509151). However, the off-label use of drugs like Ozempic for cosmetic weight loss has fueled a rise in unregulated online sales, raising significant concerns about substandard and falsified products (PMID 39509151). A comprehensive market surveillance study identified numerous illegal online pharmacies offering semaglutide without prescription (PMID 39509151). Web traffic data from July to September 2023 showed that the top 30 domains associated with illegal online pharmacies amassed over 4.7 million visits (PMID 39509151).

Test purchases from six illegal online pharmacies revealed substantial quality issues. While three injection vial purchases were delivered, none of the three Ozempic prefilled injection pens were received due to e-commerce scams (PMID 39509151). All purchased vials were deemed probable substandard and falsified products, with visual inspection identifying noncompliance in more than half (59%-63%) of the evaluated criteria (PMID 39509151). The semaglutide content in these samples was substantially compromised (PMID 39509151), illustrating the severe risks, including potential health harms, posed by products from the illicit market.

The development of bioactive peptides as potential nutraceuticals or therapeutic agents often requires scalable purification methods to obtain sufficient quantities for research and clinical trials. Lunasin, a peptide derived from the soybean 2S albumin seed protein, exhibits both anticancer and anti-inflammatory activities (PMID 22514740). However, the high cost of synthetic lunasin and the lack of methods to obtain gram quantities of highly purified lunasin from plant sources have hindered large-scale animal studies and human clinical trials (PMID 22514740).

A scalable method has been developed to generate highly purified lunasin from defatted soy flour (PMID 22514740). This method involves the sequential application of anion-exchange chromatography, ultrafiltration, and reversed-phase chromatography (PMID 22514740). It yields lunasin preparations with greater than 99% purity at a yield of 442 mg/kg defatted soy flour (PMID 22514740). Mass spectrometry of the purified lunasin confirmed it to be 44 amino acids long, matching the original published sequence with an additional C-terminal asparagine residue (PMID 22514740). Histone-binding assays, which are in-vitro studies, demonstrated that the biological activity of this purified lunasin was similar to that of synthetic lunasin (PMID 22514740). This robust purification method facilitates the development of lunasin as a potential therapeutic agent and identifies the predominant form of lunasin in soy flour (PMID 22514740).

The illicit market for performance and image-enhancing drugs, including synthetic peptides, poses significant health risks due to the unknown quality and content of products. Melanotan II, a synthetic melanocortin receptor agonist marketed as an injectable skin-tanning product, is frequently sold illegally online (PMID 24771717). New methods, including liquid chromatography with ultraviolet detection (LC-UV) at 218 nm and tandem mass spectrometric detection (MS/MS), were developed and validated to determine the identity, content, and purity of Melanotan II samples purchased from three online shops (PMID 24771717).

Identification of Melanotan II was confirmed by correct chromatographic retention time and specific relative abundance ratios of five qualifying fragment ions (PMID 24771717). LC-UV was utilized to quantify both Melanotan II and its impurities (PMID 24771717). The study revealed that vials from two shops contained unknown impurities ranging from 4.1% to 5.9%, while impurities from one shop were below the quantification limit (PMID 24771717). Despite claims by each shop that vials contained 10 mg of Melanotan II, the actual total amount of Melanotan II ranged between 4.32 mg and 8.84 mg (PMID 24771717). This significant discrepancy and the presence of impurities highlight the potential harms to users who obtain such drugs from the unregulated illicit market (PMID 24771717).

Traditional quality control procedures, especially LC-based methods, are essential but can sometimes overlook specific impurities or undeclared constituents in peptide products. The limitations of these methods become apparent when dealing with complex matrices or products sourced from unregulated channels (PMID 31671336). The presence of 'hidden' adulterants, like mannitol, in custom synthetic peptides underscores the need for more advanced and comprehensive analytical techniques (PMID 31671336).

The integration of methods such as quantitative 1H NMR (qHNMR) and Quantum-mechanical 1H iterative Full Spin Analysis (HiFSA) offers significant advantages in peptide quality control (PMID 31671336). These NMR techniques can readily detect and quantify highly polar and UV-transparent adulterants, which might be missed by conventional UV-dependent detection modes (PMID 31671336). The demonstrated utility of both high-field and benchtop qHNMR suggests that incorporating these methods with routine Certificates of Analysis (CofA) documentation and verification of research-grade chemicals can greatly enhance confidence in research and streamline pharmaceutical quality control processes (PMID 31671336).

The global prevalence of conditions like obesity and the subsequent demand for new treatments have inadvertently created opportunities for substandard and falsified peptide products to enter the market. The widespread availability of such products through unregulated online channels poses a significant threat to public health (PMID 39509151). The inability to receive products, as seen with the Ozempic prefilled injection pens in the semaglutide study, indicates potential e-commerce scams, adding another layer of risk beyond just product quality (PMID 39509151).

The lack of adherence to quality standards in the illicit market for peptides like Melanotan II, where actual content significantly deviates from claimed amounts and unknown impurities are present, exemplifies the inherent dangers (PMID 24771717). These findings collectively highlight an evolving challenge that requires continuous vigilance, advanced analytical methods, and stringent regulatory oversight to protect consumers and ensure the integrity of the scientific peptide supply chain (PMID 39509151, PMID 24771717).

• Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature. — Advances in therapy (2019). PMID 30554330
• Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. — Journal of medical Internet research (2024). PMID 39509151
• NMR reveals an undeclared constituent in custom synthetic peptides. — Journal of pharmaceutical and biomedical analysis (2020). PMID 31671336
• Scalable purification and characterization of the anticancer lunasin peptide from soybean. — PloS one (2012). PMID 22514740
• Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. — Drug testing and analysis (2015). PMID 24771717